La vendita allo scoperto per BioSig Technologies dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di BioSig Technologies. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

BioSig Technologies (NASDAQ:BSGM) Azioni, Report sulle vendite allo scoperto

BioSig Technologies

BioSig Technologies Inc is a commercial-stage medical device company with an advanced digital signal processing technology platform to deliver insights to the treatment of cardiovascular arrhythmias. Through collaboration with physicians, experts, and healthcare leaders across the field of electrophysiology (EP), It is committed to addressing healthcare's biggest priorities saving time, saving costs, and saving lives. Its first product, the PURE EP System, is an FDA-cleared non-invasive class II device consisting of a unique combination of hardware and software designed to provide unprecedented signal clarity and precision for real-time visualization of intracardiac signals paving the way for personalized patient care.

BioSig Technologies Inc

WIIM

Imperial Oil shares are trading lower after the company reported mixed Q3 financial results.

CTRA

Corterra Energy shares are trading lower after the company reported worse-than-expected Q3 adjusted EPS results and cut its FY24 capital expenditure.

B of A Securities analyst Bryan Spillane maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Neutral and lowers the price target from $100 to $75.

News

Price Target

Analyst Ratings

B of A Securities Maintains Neutral on Estee Lauder Cos, Lowers Price Target to $75

UBS analyst Jay Sole maintains Kontoor Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KTB#NYSE">KTB</a>) with a Buy and raises the price target from $103 to $110.

UBS Maintains Buy on Kontoor Brands, Raises Price Target to $110

Dayforce shares are trading higher after BMO Capital maintained an Outperform rating on the stock and raised its price target from $70 to $80.

Service Corp International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCI#NYSE">SCI</a>) reported better-than-expected third-quarter adjusted <a href="https://www.benzinga.com/quote/SCI/earnings">EPS results on Thursday</a>.
Service Corp Intl reported quarterly earnings of 79 cents per share beat the analyst consensus estimate of 77 cents per shsare. The company reported quarterly sales of $1.014 billion which missed the analyst consensus estimate of $1.016 billion.
Tom Ryan, the Company&#8217;s Chairman and CEO, commented, &#8220;Today we reported adjusted earnings per share of $0.79 and net cash provided by operating activities excluding special items of $269 million. We are excited to see the positive impact in funeral revenue from our new marketing agreement with our new preferred preneed insurance provider, which launched during the quarter. Additionally, we are pleased both funeral and cemetery gross profit were relatively stable versus the prior year third quarter with modest revenue growth reflecting our continued focus on managing fixed costs.&#8221;
Service Corp Intl said it sees fourth-quarter adjusted loss of $1.00-1.10 per share, versus estimates of 77 cents per share.
Service Corp International shares gained 0.2% to trade at $81.79 on Friday.
These analysts made changes to their price targets on Service Corp International following earnings announcement.
<ul>
<li>Raymond James analyst John Ransom maintained Service Corp Intl with an Outperform and increased the price target from $80 to $85.</li>
<li>Truist Securities analyst Tobey Sommer maintained the stock with a Buy and raised the price target from $84 to $92.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41685620/top-3-energy-stocks-that-are-preparing-to-pump-in-november">Top 3 Energy Stocks That Are Preparing To Pump In November</a></li>
</ul>

Earnings

Markets

Trading Ideas

Service Corp International Analysts Boost Their Forecasts After Upbeat Earnings

TD Cowen analyst Jeffrey Osborne maintains Generac Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>) with a Buy and raises the price target from $172 to $183.

GNRC

TD Cowen Maintains Buy on Generac Hldgs, Raises Price Target to $183

UBS analyst Eliana Merle maintains Madrigal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>) with a Buy and raises the price target from $411 to $441.

MDGL

UBS Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $441

TD Cowen analyst Jeffrey Osborne maintains Itron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRI#NASDAQ">ITRI</a>) with a Buy and raises the price target from $125 to $136.

ITRI

TD Cowen Maintains Buy on Itron, Raises Price Target to $136

Craig-Hallum analyst Anthony Stoss maintains Silicon Motion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIMO#NASDAQ">SIMO</a>) with a Buy and lowers the price target from $96 to $90.

SIMO

Craig-Hallum Maintains Buy on Silicon Motion Technology, Lowers Price Target to $90

On Thursday,&nbsp;Bristol Myers Squibb &amp; Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)&nbsp;posted third-quarter revenues of $11.89 billion, beating the consensus of $11.28 billion, an increase of 8% year-over-year, or 10% when adjusted for foreign exchange impacts, primarily driven by the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41655052/bristol-myers-squibb-boosts-2024-outlook-on-strong-demand-for-blood-thinner-med-new-drugs-drive-q" rel="noreferrer noopener">Growth Portfolio and&nbsp;Eliquis</a>.
Growth Portfolio worldwide revenues increased to $5.81 billion compared to $4.95&nbsp;billion a year ago, representing growth of 18% on a reported basis or 20% when adjusted for&nbsp;foreign exchange impacts.
BMO Capital Markets appreciates a conservative approach in the neuropsych space, though it notes management&#8217;s reserved stance on revenue expectations. It highlights that significant revenue is not expected until the second half of 2025, with a gradual launch anticipated for schizophrenia treatment.
The analyst considers the potential for Alzheimer&#8217;s psychosis treatment as an added upside, likely to positively impact sentiment.
While Bristol-Myers Squibb&#8217;s recent quarterly performance showed encouraging progress in top-line growth and cost management, its true transformation will stem from its pipeline, the BMO analyst writes.
The recent approval of Cobenfy, along with newly launched growth products, could bring the momentum investors have been anticipating.
Truist analysts noted that much of the Q3 earnings call centered on KarXT (Cobenfy), a critical asset for treating schizophrenia that could drive significant revenue and support long-term growth.
Truist analyst projects global peak sales at $4.2 billion, below the $5.4 billion consensus estimate.
While business development and partnerships are crucial to diversifying the company&#8217;s portfolio and strengthening its long-term outlook, Truist emphasized that maintaining dividends and reducing debt remain top priorities.
Price Action: BMY stock is down 1.91% at $54.71 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41686173/cancer-focused-essa-pharma-ends-prostate-cancer-trial-due-to-insufficient-efficacy-from-combinati" target="_blank" rel="noreferrer noopener">Cancer-Focused ESSA Pharma Ends Prostate Cancer Trial Due to Insufficient Efficacy From Combination Therapy</a></li>
</ul>
Image: Wikimedia Commons

Analyst Color

Biotech

Large Cap

Health Care

General

Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious

Shares of Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) are trading lower Friday amid <a href="https://www.benzinga.com/markets/equities/24/11/41677355/trump-loses-1-9b-in-net-worth-as-djt-stock-tumbles-2nd-time-this-week">continued volatility</a> leading up to the 2024 U.S. presidential election.
What To Know: With the US elections approaching, Trump Media &amp; Technology Group's stock is experiencing volatility as it is closely tied to news about former President Trump and his prospects of winning.
According to S3 Partners, DJT shares surged in October as a short squeeze forced short sellers to cover positions. S3 predicts DJT could climb to $60 if Trump wins the election, but warns it could become "worthless" if he loses. Trading in DJT has been halted several times amid rapid price movements related to election developments.
What Else: <a href="https://nypost.com/2024/11/01/business/truth-social-stock-boom-fueled-by-chatter-of-possible-sale-to-elon-musk/">Commentary from the New York Post</a> this morning speculated Elon Musk may be considering a merger or acquisition of Truth Social through X (formerly Twitter). The Post has not confirmed this speculation. 
DJT Price Action: Trump Media and Technology shares were down 11.3% at $31.34 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="530" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01132722/DJT-1024x530.png" alt="" class="wp-image-626033" style="width:519px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01132722/DJT-1024x530.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01132722/DJT-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01132722/DJT-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01132722/DJT.png 1480w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/startups/24/11/41691861/im-not-kidding-reddit-was-amazing-jim-cramer-compares-reddit-to-google-saying-choosing-between-them">&#8216;I&#8217;m Not Kidding, Reddit Was Amazing&#8217; — Jim Cramer Compares Reddit To Google, Saying Choosing Between Them Isn&#8217;t Easy</a></li>
</ul>
Image via Wikimedia Commons.

Movers

Trump Media & Technology Shares Are Dipping Today: What's Going On

UBS analyst Stephen Ju maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy and raises the price target from $223 to $230.

AMZN

UBS Maintains Buy on Amazon.com, Raises Price Target to $230

TD Cowen analyst Moshe Orenbuch maintains Credit Acceptance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CACC#NASDAQ">CACC</a>) with a Sell and lowers the price target from $400 to $380.

CACC

TD Cowen Maintains Sell on Credit Acceptance, Lowers Price Target to $380

Roth MKM analyst Scott Stember maintains Fox Factory Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXF#NASDAQ">FOXF</a>) with a Neutral and lowers the price target from $45 to $36.

FOXF

Roth MKM Maintains Neutral on Fox Factory Hldg, Lowers Price Target to $36

Roth MKM analyst Chip Moore maintains Itron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRI#NASDAQ">ITRI</a>) with a Buy and raises the price target from $125 to $130.

Roth MKM Maintains Buy on Itron, Raises Price Target to $130

<a href="https://www.bloomberg.com/news/articles/2024-11-01/chevron-flags-possible-us-job-cuts-in-3-billion-cost-cutting" title="https://www.bloomberg.com/news/articles/2024-11-01/chevron-flags-possible-us-job-cuts-in-3-billion-cost-cutting">https://www.bloomberg.com/news/articles/2024-11-01/chevron-flags-possible-us-job-cuts-in-3-billion-cost-cutting</a>

Reported Earlier: 'Chevron Flags Possible Job Cuts in $3 Billion Cost Plan' - Bloomberg

TD Cowen analyst Bill Katz maintains Janus Henderson Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHG#NYSE">JHG</a>) with a Buy and raises the price target from $46 to $50.

Janus Henderson Group plc Ordinary Shares

TD Cowen Maintains Buy on Janus Henderson Group, Raises Price Target to $50

Raymond James analyst Bobby Griffin maintains Tempur Sealy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPX#NYSE">TPX</a>) with a Strong Buy and lowers the price target from $57 to $55.

Raymond James Maintains Strong Buy on Tempur Sealy Intl, Lowers Price Target to $55

TD Cowen analyst Moshe Orenbuch maintains Navient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAVI#NASDAQ">NAVI</a>) with a Sell and lowers the price target from $14 to $13.

NAVI

TD Cowen Maintains Sell on Navient, Lowers Price Target to $13

An announcement from BioSig Technologies Inc (BSGM) is now available. BioSig Technologies, Inc. has strengthened its board with the appointment of ...

BioSig Technologies Bolsters Board with Strategic Appointments

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
BioSig Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/bsgm-stock-quote/">BSGM</a>) just reported results for the first quarter of 2024.<ul><li>BioSig Technologies reported earnings per share of -36 cents.</li><li>The company reported revenue of $14,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/bsgm-stock-earnings-biosig-technologies-for-q1-of-2024/">BSGM Stock Earnings: BioSig Technologies Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BSGM Stock Earnings: BioSig Technologies Reported Results for Q1 2024

Salesforce, Nutanix, Bruker among premarket losers' pack

BioSig Technologies slumps 18% on $3M equity sale

Predictive Oncology, Augmedix, Cue Health among healthcare movers

BioSig Technologies (BSGM) has provided an update. BioSig Technologies, Inc. has appointed Ferdinand Groenewald as their interim chief financial of...

BioSig Technologies Announces CFO Transition and New Appointment

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
BioSig Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/bsgm-stock-quote/">BSGM</a>) just reported results for the second quarter of 2024.<ul><li>BioSig Technologies reported earnings per share of -30 cents. This was below the analyst estimate for EPS of -10 cents.</li><li>The company reported revenue of $13,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/bsgm-stock-earnings-biosig-technologies-for-q2-of-2024/">BSGM Stock Earnings: BioSig Technologies Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BSGM Stock Earnings: BioSig Technologies Misses EPS for Q2 2024

Nvidia-backed Recursion hurts AI biotechs on mixed data for lead drug

BioSig Technologies ( ($BSGM) ) has provided an update. BioSig Technologies, Inc. has seen a leadership change with Kenneth L. Londoner stepping do...

BioSig Technologies Announces Executive Leadership Overhaul

BioSig Technologies (BSGM) announced its successful appeal to the Nasdaq Panel, and as a result the company's common stock will resume trading on t...

BioSig Technologies to resume trading on Nasdaq following successful appeal

ABCL

ABSI

ALHC

AUGX

BNAI

BRKR

BSGM

EXAI

GANX

HLTH

MAXN

NTNX

NVDA

ONMD

PATH

POAI

RXRX

SDGR

SGHT

Contracts

Press Releases

BioSig Engages Consulting Firm for Business Model Strategies

Management

BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately

BioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent

BioSig Technologies Chief Executive Officer Mr. Anthony Amato Issues the Following Letter to Shareholders

Financing

BioSig Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BioSig Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer

BioSig Technologies Improves Balance Sheet, Announces Reduction in Outstanding Payables during Q2 2024

BioSig Technologies Announces Intent to Acquire the Assets of Neuro-Kinesis Corporation

BioSig Technologies' Common Stock to Resume Trading on the NASDAQ Exchange, Wednesday, October 23, 2024 After Its Successful Appeal to the NASDAQ Panel

Comments

BioSig Technologies

Vendite allo scoperto

BioSig Technologies (NASDAQ:BSGM) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO